long intergenic non-protein coding RNA 1685Genealiases: []
Q-omics provides the consensus-scored LINC01685 profile across patient tissues and cancer cell-line models. LINC01685 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, LINC01685 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC01685 RNA expression shows 6,474 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, KIRC, and STAD as cancer lineages where LINC01685 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01685 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01685 survival associations across molecular data types. LINC01685 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01685 RNA expression–survival associations across cancer types. High LINC01685 expression shows unfavorable associations in TGCT, SKCM, OV and MESO, but favorable associations in HNSC and CHOL. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify TGCT as the clearest survival context for LINC01685 RNA expression.
This table summarizes LINC01685 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01685. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01685 shows lower tumor expression in KIRC, KIRP, KICH, LUSC and COAD. The KIRC box plot shows higher LINC01685 RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p < 0.001).
This table shows molecular features associated with LINC01685 in patient tissues and cancer cell lines. In patient samples, LINC01685 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
